Organisation paid for research Program year 2024 Source: CMS Open Payments

Bay Area Heart

Neither a doctor nor a teaching hospital

Research payments

$225,448

7 payments

Through program year 2024, Bay Area Heart is reported as receiving $225,448 in research payments, across 7 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2024	Research	$6,179	1
2023	Research	$51,965	2
2022	Research	$113,426	1
2021	Research	$1,985	1
2019	Research	$51,893	2

Breakdown

Who paid Research payments · program years 2019–2024

Novartis Pharmaceuticals Corporation $225,448 7 payments

Studies the money was for Research payments · program years 2019–2024

A Randomized, Multicenter, Open-Label Trial Comparing the Effectiveness of An Inclisiran First Implementation Strategy to Usual Care on LDL Cholesterol (LDL-C) in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C (?70 MG/D $113,426 1 payment
A randomized, multicenter, open-label trial comparing the effectiveness of an "inclisiran first" implementation strategy to usual care on LDL cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease and elevated LDL-C (70 mg/dL) despite receiving maximally tolerated statin therapy (VICTORION-INITIATE) $58,144 3 payments
Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor Arni Versus Ace Inhibitor Trial to Determine Impact on Serious Events After Myocardial Infarction Paradise Mi $43,824 1 payment
Prospective Comparison of Combined Angiotensin Neprilysin Inhibition With Lcz696 Relative to Enalapril on Central Aortic Stiffness and Ventricular Vascular Coupling in Patients With Heart Failure and Reduced Ejection Fraction $8,068 1 payment
A Randomized, Multicenter, Open-Label Trial Comparing the Effectiveness of An ""Inclisiran First"" Implementation Strategy to Usual Care on LDL Cholesterol (LDL-C) in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C (?70 MG/DL) Despite Receiving Maximally Tolerated Statin Therapy (Victorion-Initiate) $1,985 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.